The world’s largest clinical trial on cannabidiol (CBD) as a treatment for insomnia has been given the green light to
On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA
Ananda Pharma has taken another major step forward in bringing its flagship MRX1 CBD oral solution to market. Today (June
For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete
The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”JAZZ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Epidiolex (Epidyolex in the EU
In the intricate landscape of medical cannabis, Belgium has established a regulated framework to govern the use of cannabis for
Jazz Pharmaceuticals Jazz Pharmaceuticals, which has become the world’s largest exporter of medical cannabis products since it bought GW Pharmaceuticals
IT has been a difficult year for cannabis investors, and as the dreaded bear continues to hit global markets, many
Jonathan Havens of Saul Ewing Arnstein & Lehr LLP to talk about what the US FDA’s approval of GW Pharma’s
We won’t spam you
